Details

Autor(en) / Beteiligte

• Maio, M
• Ascierto, P A
• Manzyuk, L
• Motola-Kuba, D
• Penel, N
• Cassier, P A
• Bariani, G M
• De Jesus Acosta, A
• Doi, T
• Longo, F
• Miller, Jr, W H
• Oh, D-Y
• Gottfried, M
• Xu, L
• Jin, F
• Norwood, K
• Marabelle, A

Titel

Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study

Ist Teil von

• Annals of oncology, 2022-06, Vol.33, p.P929-938

Ort / Verlag

England: Elsevier

Erscheinungsjahr

2022

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Pembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors in the phase 2 multicohort KEYNOTE-158 (NCT02628067) study. Herein, we report safety and efficacy outcomes with longer follow-up for more patients with previously treated advanced MSI-H/dMMR noncolorectal cancers who were included in cohort K of the KEYNOTE-158 (NCT02628067) study. Eligible patients with previously treated advanced noncolorectal MSI-H/dMMR solid tumors, measurable disease per RECIST v1.1, and ECOG performance status of 0 or 1 received pembrolizumab 200 mg Q3W for 35 cycles or until disease progression or unacceptable toxicity. The primary endpoint was ORR per RECIST v1.1 by independent central radiologic review. Three hundred and fifty-one patients with various tumor types were enrolled in KEYNOTE-158 cohort K. The most common tumor types were endometrial (22.5%), gastric (14.5%), and small intestine (7.4%). Median time from first dose to database cutoff (October 5, 2020) was 37.5 months (range, 0.2‒55.6 months). ORR among 321 patients in the efficacy population (patients who received ≥1 dose of pembrolizumab enrolled ≥6 months before the data cutoff date) was 30.8% (95% CI, 25.8‒36.2). Median duration of response was 47.5 months (range, 2.1+ to 51.1+ months). Median progression-free survival was 3.5 months (95% CI, 2.3‒4.2 months) and median overall survival was 20.1 months (95% CI, 14.1‒27.1 months). Treatment-related AEs occurred in 227 patients (64.7%). Grade 3‒4 treatment-related AEs occurred in 39 patients (11.1%); three had (0.9%) grade 5 treatment-related AEs (myocarditis, pneumonia, and Guillain-Barre syndrome, n=1 each). Pembrolizumab demonstrated clinically meaningful and durable benefit, with high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting.